Listing of Color Additives Exempt From Certification; Spirulina Extract
Published Date: 2/6/2026
Rule
Summary
The FDA is giving a green light to use spirulina extract as a natural food color in most human foods, with safer limits on heavy metals like lead and mercury. This change helps food makers use a vibrant, plant-based color while keeping products safer. The new rules kick in on March 23, 2026, and anyone can raise concerns by March 9, 2026.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Lower heavy-metal limits for safety
The FDA set specific maximum contaminant limits for spirulina extract: lead not more than 0.2 mg/kg (0.2 ppm), arsenic not more than 0.3 mg/kg (0.3 ppm), mercury not more than 0.1 mg/kg (0.1 ppm), cadmium not more than 0.3 mg/kg (0.3 ppm), and the product must be negative for microcystin toxin. These specifications are part of the final order effective March 23, 2026.
Spirulina allowed in most foods
The FDA now allows spirulina (Arthrospira platensis) extract to be used as a natural color in human foods generally at levels consistent with good manufacturing practice, effective March 23, 2026. It may not be used in infant formula, foods regulated by the U.S. Department of Agriculture (meat, poultry, egg products), or foods with standards of identity unless those standards specifically allow it.
No spirulina in infant formula
The FDA specifically prohibits use of spirulina extract in infant formula under the final order effective March 23, 2026. Parents and caregivers should not expect infant formulas to contain this color additive.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2026-02313 — Listing of Color Additives Exempt From Certification; Beetroot Red
The FDA is giving the green light for beetroot red to be used as a safe food color in most human foods, except for certain USDA products, infant formula, and foods with special color rules. This change starts March 23, 2026, and food makers can now use this natural color without extra certification. If anyone wants to object or ask for a hearing, they must do so by March 9, 2026.
Next: 2026-02319 — Amendment of Class E Airspace; Beeville, TX
The FAA is updating the Class E airspace around Beeville, TX, because a nearby navigation beacon was turned off. This change helps keep flights safe and smooth for pilots using instruments to fly. The new airspace rules kick in on May 14, 2026, with no extra costs for anyone.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in